San Francisco, California-- (Newsfile Corp. - February 20, 2025) - BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Methods Patients with RA in the Clinical Practice Research Datalink starting MTX between 1987 and 2016 were included. Hepatotoxicity was defined as transaminitis: alanine transaminase or aspartate ...

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Her hospital course was complicated by transaminitis. Her platelet count improved to normal on hospital day 5 after receiving intravenous steroids and intravenous immunoglobulin to treat her suspected ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired ...

Glucarpidase (Voraxaze, BTG International) also accelerated kidney recovery time and resulted in lower odds for other adverse events, including neutropenia and transaminitis. “Especially for ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

The decision follows observations of liver transaminitis without clinically significant symptoms, and without clear dose dependence, in some patients in the azelaprag arms of the STRIDES Phase 2 ...

Given the fact that defendants failure to disclose the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies, defendants' statements ...